Edition:
United States

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

12.05USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$12.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
176,040
52-wk High
$24.70
52-wk Low
$8.07

Chart for

About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab... (more)

Overall

Beta: 3.42
Market Cap(Mil.): $754.94
Shares Outstanding(Mil.): 60.15
Dividend: --
Yield (%): --

Financials

  CHRS.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -4.55 -- --
ROI: -184.16 -0.75 13.17
ROE: -909.90 -2.86 14.98

BRIEF-Coherus Biosciences Says U.S. Court Grants Motion To Dismiss Patent Infringement Complaint

* COHERUS BIOSCIENCES-U.S. COURT ADOPTED MAGISTRATE JUDGE BURKE'S REPORT & RECOMMENDATION TO GRANT MOTION OF CO TO DISMISS PATENT INFRINGEMENT COMPLAINT

Mar 26 2018

BRIEF-Coherus BioSciences Reports Q4 Loss Per Share $0.84

* COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million

* COHERUS BIOSCIENCES SAYS ‍HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING​ Source text : (http://bit.ly/2qqVZLs) Further company coverage:

Jan 05 2018

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM

Dec 08 2017

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

Nov 14 2017

BRIEF-Coherus Biosciences Q3 loss per share $1.09

* Coherus Biosciences reports third quarter 2017 operating and financial results

Nov 06 2017

Competitors

Earnings vs. Estimates